Dataset Information

Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment.

ABSTRACT: We evaluated changes in oral diabetes mellitus medication adherence and persistence, as well as glycemic control for the year prior to breast cancer (BC) diagnosis (Year -1), during BC treatment, and in subsequent years.Cohort study of 4216 women diagnosed with incident early stage (I and II) invasive BC from 1990-2008, enrolled in Group Health Cooperative. Adherence was measured in prevalent users at baseline (N?=?509), during treatment, and 1-3?years post-diagnosis using medication possession ratio (MPR), % adherent (MPR ?0.80) and discontinuation rates. Laboratory data on glycosylated hemoglobin (HbA1c ) was obtained for the corresponding periods.Compared with Year -1, mean MPR for metformin/sulfonylureas (0.86 vs 0.49, p?7.0% (34.9% vs 51.1%, p?

SUBMITTER: Calip GS

PROVIDER: S-EPMC4265308 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment.

Calip Gregory S GS Hubbard Rebecca A RA Stergachis Andy A Malone Kathleen E KE Gralow Julie R JR Boudreau Denise M DM

Pharmacoepidemiology and drug safety 20140613 1

<h4>Objectives</h4>We evaluated changes in oral diabetes mellitus medication adherence and persistence, as well as glycemic control for the year prior to breast cancer (BC) diagnosis (Year -1), during BC treatment, and in subsequent years.<h4>Methods</h4>Cohort study of 4216 women diagnosed with incident early stage (I and II) invasive BC from 1990-2008, enrolled in Group Health Cooperative. Adherence was measured in prevalent users at baseline (N = 509), during treatment, and 1-3 years post-dia ...[more]

PMID: 24923811

Similar Datasets

Project description:Diabetes is associated with a higher risk for adverse cardiovascular outcomes. To improve the health outcomes of patients with type 2 diabetes (T2DM), the American Diabetes Association (ADA) recommended target goals for the improvement of glycemic control and the reduction of cardiovascular risk factors associated with the disease. This retrospective analysis calculated the absolute benefit increase (ABI) of using exenatide once weekly (QW), a glucagon-like peptide-1 (GLP-1) receptor agonist, vs an oral glucose-lowering medication or insulin glargine to achieve ADA-recommended goals. The number needed to treat (NNT) to achieve these goals was also calculated and provides a useful clinical metric for comparing potential therapies from different drug classes.Patient data from three double-blind or open label, 26-week, randomized, controlled trials were retrospectively analyzed separately. ABI and NNT were calculated by comparing the percentage of patients treated with exenatide QW (N = 641) vs metformin (N = 246), sitagliptin (N = 329), pioglitazone (N = 328), or insulin glargine (N = 223), who achieved a single glycemic, weight, blood pressure, or lipid goal or a composite of these recommended goals, during the DURATION-2, -3, and -4 clinical trials.Significant ABIs favoring exenatide QW over all four glucose-lowering medications were observed for at least one HbA1c glycemic goal. NNTs of 4 and 5 were calculated when exenatide QW was compared to sitagliptin for attaining HbA1c goals of <7.0% and ?6.5%, respectively. Additionally, significantly more patients using exenatide QW compared to sitagliptin, pioglitazone, or insulin glargine attained the composite goal of HbA1c <7% or ?6.5%, without weight gain or hypoglycemia. Exenatide QW was also favored over sitagliptin and insulin glargine for the achievement of the composite goals of HbA1c <7% (or ?6.5%), systolic blood pressure <130 mm Hg, and low-density lipoprotein <2.59 mmol/L. For most goals, exenatide QW and metformin had similar effects in treatment naïve patients.This analysis assessed the between-therapy differences in achieving therapeutic goals with therapies commonly used for glycemic control in patients with T2DM. In clinical trials, exenatide QW assisted more patients in reaching the majority of ADA-recommended therapeutic goals than treatment with sitagliptin, pioglitazone, or insulin glargine.NCT00637273, NCT00641056, NCT00676338.

Dataset Information

Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment.

Publications

Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets